FOSUN复星

Financial Results for the Full Year 2017

March 27, 2018





智。行 NTELLIGENCE IN ACTION

Disclaimer

It is not the intention of this document to provide a full explanation of any relevant matters of Fosun International Limited. (the "Company"). You must refrain from relying on any information set out in this document. No statement, guarantee or undertaking is or will be made or given at present or in the future in respect of the accuracy, fairness, reasonableness, correctness or completeness of this document or any information or opinions set forth herein or any other information or opinions, whether written or oral, available to any stakeholder or its advisers, nor is there or will there be any express or implied indication made in respect of the above content at present or in the future. None of the Company or any of its shareholders, directors, officers, employees, affiliates, advisers or representatives (the "Parties") shall assume any liability, including but not limited to liability for default, for or in respect of the above content at present or in the future. The Parties expressly state that they shall not be held liable for any loss resulting from the use of this document or its content or in any other manner in connection with this document. It is assumed that information set out in this document is appropriate for the current situation and such information could be subject to change without notice. None of the Parties shall be held liable for procuring the receipt of information under this document by any recipients, updating information under this document, or correcting any manifest error contained under this document. In the event of any conflict between this document and the annual results announcement of the Company for the whole year of 2017 (collectively, the "Annual Documents"), the Annual Documents shall prevail.

Cautionary Statement Regarding Forward-Looking Statements

This PPT includes forward-looking statements. All statements, other than statements of historical facts, that address activities, events or developments that Fosun International Limited (the "Company") expects or anticipates will or may occur in the future (including but not limited to projections, targets, estimates and business plans) are forward-looking statements. The Company's actual results or developments may differ materially from those indicated by these forward-looking statements as a result of various factors and uncertainties, and other risks and factors beyond our control. In addition, the Company makes the forward-looking statements referred to herein as of today and undertakes no obligation to update these statements. The financial figures in this PPT are calculated using the average exchange rate for the reporting period January 2017 to December 2017 (USD/CNY= 6.7423 HKD/CNY= 0.8650), and period-end exchange rate as of 2017/12/31 (USD/CNY=6.5342 HKD/CNY=0.8359), unless otherwise stated.

Table of contents



- 1 Results highlights
- 2 Financial review
- 3 Business review
- 4 C2M strategy
- 5 Outlook
- A Appendix



Results Highlights

Total Revenue

88.03 billion

Y-o-Y increase of 19%

• RMB73.97 billion in 2016, Y-o-Y growth: Health 24%, Happiness 12%, Wealth 19%

Adj. Net Asset Value per share ³

HKD

33.28

Y-o-Y increase of 28%

- HKD26.01 as at Dec 31, 2016
- Implied 46% discount to last closing price⁴

Profit attributable to owners of the parent

13.16 billion

Y-o-Y increase of 28%

• RMB10.27 billion in 2016, Y-o-Y growth: Health 32%, Happiness 6%, Wealth 29%

Earnings Per Share

HKD

1.77_(RMB 1.53)

Y-o-Y increase of 29%⁵

- HKD1.39 (RMB 1.19) in 2016
- 5 year CAGR of 21%⁵

Net Gearing (%)1

49.7%

Deleveraging over past 5 years

- 60.3% at end of 2016
- Moody's upgraded rating to 'Ba2 stable'2

Dividend per share⁶

HKD

0.35

Y-o-Y increase of 67%

- HKD0.21 in 2016
- Payout ratio of 20% (16% in 2016)

12 CACD of 01075

Note: 1. Net Gearing ratio = net debt / equity, net debt = total debt - cash and bank balances and term deposits; 2. In January 2018; 3. Adjusted NAV = market value of listed investments held by the Group + fair value of unlisted investments utilizing recent transactions or comparable companies method - the Group's net debt; 4. As at 27 March 2018; 5. calculated in RMB; 6. The proposal of the board of directors is subject to adoption by the general meeting of shareholders.

Results Highlights (con't)









- Fosun Pharma, Henlius, Foliday, Proxima
- · Integrate technology, talent, marketing & customers



- Global platform for M&A / capital markets
- Turnaround and improve operations



• Improving product competitiveness through

technology and innovation





Note1: Official Unicorns recognized by the Chinese Ministry of Science and Technology include investments by the Group: Henlius, WeDoctor, Cainiao etc.

2 FINANCIAL REVIEW



Continued profit growth with new record high EPS 智。行


	2017	2016	YoY Change(%)	
Net profit attributable to owners of the parent (RMB bn)	13.16	10.27	28.2%	
Basic earnings per share	RMB 1.53 (HKD 1.77)	RMB 1.19 (HKD 1.39)	28.6%	

HKD	2017/12/31	2016/12/31	YoY Change(%)
NAV per share	14.07	12.01	17.2%
Adjusted NAV per share ¹	33.28	26.01	28.0%

Note: 1. Adjusted NAV = market value of listed investments held by the Group + fair value of unlisted investments utilizing recent transactions or comparable companies method - the Group's net debt.

Net Profit has grown 29% every year







Health, Insurance and Finance driving growth



Profit attributable to owners of the parent



Capital structure optimized



Balance Sheet								
	2013	2014	2015	2016	2017			
Net debt (RMB bn)	52.70	55.50	67.89	74.12	67.84			
Net gearing (%) 1	86.0%	73.3%	68.2%	60.3%	49.7%			
Net debt/EBITDA	3.7x	3.0x	2.8x	3.1x	2.2x			
Total undrawn facilities (RMB bn)	77.64	107.16	132.28	158.33	161.67			
Average cost of debt	5.73%	5.61%	4.97%	4.47%	4.72%			

Notes: 1. Net gearing = net debt/equity, net debt=total debt-cash, bank and term deposits



C2M strategy now driving shareholder value





Net profit grew 28.2% to RMB 13.16 billion

Adj. NAV grew 28.0% to HKD 33.28 per share

3 66.7% increase in Dividend per share to HKD 0.35




Health Ecosystem



Maintained growth in high-quality core operations

- Significant progress in technological innovation and global strategies
- Consolidation into the leading player in health industry



Happiness Ecosystem

智。行

Established Tourism & Culture Group and Fashion Group - pureplay platforms to enhance operations

Turnaround success through operational efficiency at Yuyuan, Club Med and Tom Tailor

3 Yuyuan restructuring in an orderly manner

Club Med[‡]!

Opened 2 new resorts in 2017 & 2 'Joyview' villages in Jan 2018. Serving >1.3mn customers in 2017 with resort operating profit increasing by 16.6% in 2017

ATLANTIS

SANYA 三亚·亚特兰蒂斯

Fosun's new destination resort in Sanya. Soft launch in Feb 2018 with ~5,000 daily visitors during CNY. Official launch 1H 2018

LANVIN

Announced acquisition of iconic French fashion house¹ in Feb 2018

豫 园 股 份 YUYUAN Inc.

Net profit grew 46.24% in 2017. Restructuring conditionally approved by CSRC in Jan 2018. Upon completion, Fosun will increase stake to 68%

ourism & Leisure

Fashior

Consumer & Lifestyle

FOLIDAY 复星旅文

Officially established in 2017, focus on the needs of middleclass families, and committed to providing high-quality leisure and travel experiences for alobal customers TOM TAILOR

Fosun actively participated in restructuring plan and fully empowered and helped Tom Tailor expand into new markets, with Cagr 1,450% for past 2 years

FosunFashion

Established in Mar 18 to operate a global fashion brands and to build a competitive portfolio to leverage China's booming consumption market



Acquired 17.99% interest in Tsingtao Brewery² for HK\$6.6bn in Dec 2017. Completed in Mar 2018

Note: 1. Transaction not yet completed; 2. Invested by the Group and a fund managed by the Group,

14


Wealth Ecosystem

智。行

Significant growth in insurance and financial sectors

10 IPOs (in China, USA, Germany and Hong Kong)

Continued strategy to invest and develop financial technology



Hangzhou-Shaoxing-Taizhou

High Speed Railway started in December 2017

to RMB39.0bn and 633%

increase in PRT to RMB4 29bn

China Unionpay, In 2017,

successfully turned losses

into net profit of EUR186mn

Value creation through three stages



Technology innovation

Happiness

Wealth

Health

FOSUN PHARMA 复星医药

Stage 3: Industry leader

- Become industry leaders with scalable business
- Lead through technology and innovation
- Build top management team

Club Med[‡]





TOM TAILOR



FIDELIDADE















Stage 2: Integrated operation

- Formulate long-term strategy
- Focus on performance incentives
- Provide ONE Fosun platform supporting talent, technology, marketing channels, membership

FNAGA

FONOVA 星济大数据



















Stage 1: Enter Industry

- Enter industry through acquisitions
- Create operating pureplays
- Cultivate industry leaders through operations





Focus on family customers



Health ecosystem

7.5 million +7.8%

Fosun Pharma and Luz Saúde annual in-and-out patients

38 million

Registered online users (maternal)

Happiness ecosystem

40 million

Yuyuan annual visitors

1.3 million

Club Med annual visitors

>35 million family users¹

Wealth ecosystem

2.9 million

Fidelidade customers

5.4 million

+6.0%

BCP active customers




Successful turnaround stories





WANBANG

- Greatly enhanced R&D, marketing and branding capabilities;
- Assisted Wanbang to broaden scope from a single pharmaceutical company into a group with 14 member companies:
- Provided incentivization scheme to attract and retain talent



Resort operating profit


Club Med [¶].

- Focus on performance incentives
- Enhanced digital capabilities
- Shared Fosun supply chain: one link⁺
- China strategy:

 Joyview+Miniversity

 asset-light strategy





■ Profit before tax

2017 Q3

Eur mn

2016 Q3

Hauck & Aufhäuser


- Optimize mat team
- Increase access to China market
- Connected to FinTech company to create new solutions for customers

● 佛▲市禪城中心醫院 Foshan Chancheng Central Hospital

- Optimized strategy positioning
- Supported development of 'smart' hospital
- Member companies share resources and refer businesses to each other. They can also link their offline and online operations
- Created a cross-border model: cooperating with Albion in the form of "healthcare + hotel"




- Reshaped and optimized the team
- Optimized operating cost control
 - Enhance product mix: reduce the proportion of unpopular SKU
- New branding strategy



FIDELIDADE

- "Insurance +
 Investment" strategy:
 return on investment in
 2017 outperforms the
 market by more than
 200bps
- An elite team, incentive scheme for the talent
- Strengthening the company through M&A



■ Net Profit



19

Tech & innovation to enhance operations in biotech & intelligent technology



Biotech HLX01 is likely to become the first Biopharmac-Menlius generic biological drug in China. euticals Production of high-quality and affordable drugs to benefit more patients To heal B-cell lymphoma and Cellular **FOSUNKite** leukemia **Immune** Greatly increase the overall **Therapy** response rate of relapsed/refractory lymphoma patients The most advanced minimum invasive surgery system in the world INTUĬTIVE Robotic Committed to research on next 直观复星 aeneration machine of diagnoses Surgery and treatment on early lung cancer Significantly improves results of surgery, shorten the length of stay in hospital and recovery time

Intelligent Technology **□** JIGUANG | 桁光 Detailed profile of consumers **Big Data** Precision marketing Cross marketing Applicable to One Fosun platform Potential areas: 1) Financing, Onchain payment and clearing **Blockchain** 2)Supply chain management 3) Protection of digital intellectual property Internet of Telematics system THE FLOOW Insurance pricing Thinas Dedicated to building the best-in-class benefits and you lè 有叻 Household experiences, thereby, **Members** increasing consumers' satisfaction Precision marketing and cross-marketina

Artificial Intelligence





Intelligent system for medical diagnosis reduces human errors Improves efficiency and effectiveness of doctors' diagnosis

智。行

5 Outlook






Continuously strengthen C2M & technological innovation







Foundation assets: provide stable and consistent cash flow and profit to support C2M strategy



Note: 1. Transaction not yet completed





APPENDIX

Board of directors and key management







Chairman Mr Guo Guangchang

CEO Mr Wang Qunbin

Co-Presidents Mr Chen Qiyu

Mr Xu Xiaoliang

SVP Mr Qin Xuetang

SVP, CFO Mr Robin Wang

SVP Ms Kang Lan

SVP Mr Gong Ping

























>30 Global Partners





Insurance business overview



Insurance





ase

PeakRe >





FOSUN HEALTH 复星联合健康保险

Fosun Insurance Portugal

- European composite insurance company
- Shareholding ratio: 84.9861%

AmeriTrust1

- American labor insurance company
- Shareholding ratio: 100%

Peak Reinsurance

- Hong Kong reinsurance company
- Shareholding ratio: 86.93%

Pramerica Fosun

- Chinese life insurance company
- Shareholding ratio: 50%

Yong'an P&C Insurance

- Chinese property insurance company
- Shareholding ratio: 40.68%

Fosun United Health Insurance

- Chinese health
 insurance company
 Sharehalding ration
- Shareholding ratio: 20%

Investable Asset²

Unit: RMB Bn	Investabl	nvestable Asset ³			
	2016/12/31	2017/12/31			
Fosun Insurance Portugal	100.71	116.80			
Peak Reinsurance	8.46	10.06			
Pramerica Fosun	2.02	3.77			
Yong'an P&C Insurance	11.35	10.65			
AmeriTrust	10.68	10.53			
Total equity ⁴	109.25	124.76			

Insurance asset spread²

	Cost of investable asset 3 2016 2017		Total ret investn (RO	nent ³	Spread based on ROI		
			2016	2017	2016	2017	
Fosun Insurance Portugal	1.0%	0.8%	3.2%	3.6%	2.2%	2.8%	
Peak Reinsurance	-1.1%	5.5%	1.5%	7.1%	2.6%	1.6%	
Pramerica Fosun	11.4%	11.6%	3.9%	7.1%	-7.5%	-4.5%	
Yong'an P&C Insurance	-1.1%	3.4%	7.2%	7.4%	8.3%	4.0%	
AmeriTrust	1.1%	1.2%	3.2%	4.3%	2.1%	3.1%	
Total equity ⁴	0.9%	1.4%	3.3%	4.1%	2.4%	2.7%	

Insurance asset configuration²

Proportion				
2016/12/31	2017/12/31			
66.8%	74.9%			
13.1%	10.7%			
11.1%	8.3%			
9.0%	6.1%			
	2016/12/31 66.8% 13.1%			

Note:

- 1. Formerly known as MIG:
- 2. Due to the completion of the disposal of Ironshore in 1H2017, the table excludes Ironshore data;
- 3. Calculation formula:
- > Investable asset refer to the insurance float used by insurance company (from insurance businesses' funds precipitation), capital invested by shareholders, retained earnings etc., assets formed by various domestic and overseas investment activities. It mainly includes fix income investment, equity investment, infrastructure investment, real estate investment and cash and cash equivalents

27

- > Cost of investable asset is estimated based on the underwriting profit, interest attributable to insured parties and dividend
- > Return on investment =(net investment income + bid-ask spread + profits and losses from changes in fair value of trading financial assets + investment asset impairment loss+ associated enterprises' profits and losses confirmed by equity method) / average invested assets

4. Investable asset and insurance asset spread of the individual insurance company are based on general accounting standards applicable to the place of supervision. Equity holds by Fosun is added to the effective portion

Top 20 secondary holdings 1 (as at Dec 31, 2017)

INTELLIGENCE IN ACTION

No.	Stock Name	% Held ²	Market value (RMB bn)	Market value (USD bn)
1	Fosun Pharma (A+H) ³	37.94%	42.10	6.44
2	Hainan Mining ³	51.57%	8.92	1.37
3	BCP	27.06%	8.62	1.32
4	Focus Media	5.00%	8.61	1.32
5	New China Life ⁴	4.58%	6.37	0.98
6	Nanjing Iron&Steel ⁵	26.08%	5.55	0.85
7	Yuyuan Inc.	26.45%	4.08	0.62
8	Ageas	3.81%	2.53	0.39
9	Zhongshan Public Utilities	12.35%	1.87	0.29
10	Sanyuan Foods	18.04%	1.73	0.27
11	Grandland Group	11.63%	1.45	0.22
12	Jinjia Group	9.18%	1.27	0.19
13	Sun Paper Group	4.75%	1.14	0.17
14	Juewei Food	7.02%	1.14	0.17
15	Folli Follie	10.00%	0.99	0.15
16	Yunda Holding	1.61%	0.75	0.11
17	Thomas Cook	3.99%	0.66	0.10
18	Cosmo Lady	11.18%	0.57	0.09
19	Fanhua Inc.	6.14%	0.56	0.09
20	Poten Environment Group	2.97%	0.41	0.06
		Total	99.32	15.20

Note

- Include 2nd market investment by the Company, its investment platforms, special-purpose entities and consolidated funds, exclude other subsidiaries' or associates' or joint ventures investment;
- 2. Percentage of effective equity interest;
- 3. The Company's subsidiaries;
- 4. Fosun International and Fosun High Technology collectively hold 2.74% equity interest of New China Life and another 2.27% indirectly via a JV, which sum up to 5.01%. Effective equity interest held by Fosun International is 4.58%:
- 5. Fosun High Technology holds 60% in Nanjing Nangang, which holds 43.47% in Nanjing Iron & Steel with its subsidiaries

Value Realization through operations and balanced capital allocation



Last three years sees growing value realization with:

- > 100 investments¹ (64% of the investments are in the sectors of health and happiness, 40% in technology related investments), >50 divestments¹, 10 IPOs
- Bund Finance Center and L28 opens
- Atlantis resort completed and fully opens in 1H 2018











2013

Sısram

28 LIBERT Lloyds Chamber

2014

2015

2016

2017

2018


Note:

- Excluding investments and divestments by insurance companies, associate & joint ventu companies
- 2. Transaction not vet completed

Value Realization Capital Allocation

Global footprint¹





Note:

- 1. Diagram shows selection of Fosun portfolio companies
- 2. Transaction not yet completed.

Simplified corporate structure¹



Health Ecosystem Happ			oiness Ecosystem		Wealth Ecosystem					
Pharmaceutical	Medical Services & Health Management	Health Products	Tourism & Leisure	Fashion	Consumer & Lifestyle	Insurance	and Finance	Inve	stment	Hive Property
Fosun Pharma 37.94%	Fosun United Health Insurance ² 20.00%	Silver Cross 87.23%	Club Med ⁶ 90.10%	LANVIN ⁸	YuYuan Inc 26.45%	Fosun Insurance Portugal ¹⁵ 84.9861%	Fosun Hani Securities 100.00%	Fosun Capital 100%	Nanjing Nangan 60.00%	Forte 100.00%
Sinopharm	Chancheng Hospital	Sanyuan Foods ⁴ 20.45%	Atlantis 99.81%	Tom ⁹ Tailor 28.89%	Tsingtao ¹⁴ 17.99%	Ameri Trust 100.00%	H&A 99.91%	IDERA 98.00%	Koller ¹⁶ 84.50%	28 Liberty 100.00%
Gland Pharma	Luz Saúde ³ 98.79%	St Hubert 98.12%	Thomas ⁷ Cook 11.22%	Wolford 10	AHAVA 99.46%	Peak Re 86.93%	BCP 27.06%	Focus Media 5.00%	Besino ¹⁷ Environment 100.00%	BFC 50.00%
Sisram	United Family			Caruso ¹¹ 73.9%		Pramerica Fosun 50.00%	MyBank 25.00%	Cainiao 6.77%	Roc 100.00%	
We Doctor	Starcastle Senior Living 50.00%			St John ¹² 70.00%	FolliFollie ¹³ 13.89%	Yong'an P&C Insurance 40.68%			Hainan Mining 51.57%	

- 1. This simplified corporate structure illustrates the key investments of the Group only. 5. The Group co-invested with Sanyuan Foods in St Hubert in July 2017, the The equity percentage reflects the total direct shareholdings held by the Group. associates, joint ventures and funds managed by the Group as at 31 December 2017. The companies marked in the dotted box are invested by Fosun Pharma. For specific information, please refer to the disclosure of Fosun Pharma. The companies marked in the shadow box are the projects remained to be completed as at the end of the Reporting Period.
- 2. It is listed under the seament of "Insurance and Finance" when accounting treatment is processed
- Fidelidade, a subsidiary of the Group held 98.79% equity interest in Luz Saúde. Therefore, the Group held 83.96% effective equity interest in Luz Saúde.
- 4. The Group through its wholly-owned subsidiary, and Shanghai Fosun Chuanghong Equity Investment Fund Partnership (L.P.) ("Fosun Chuanghong"), a fund under management of the Group held 16.67% and 3.78% equity interest, respectively, in Sanyuan Foods. The Group held Fosun Chuanghong general partnership interest and limited partnership interest of totally 36.22%, thus, the Group held 18.04% effective equity interest in Sanyuan Foods.
- transaction was completed in January 2018. St Hubert is held as to 98.12% by an associate (the Group held 51% equity interest in such associate). Therefore, the Group held 50.04% effective equity interest in St Hubert.
- Club Med is held as to 68.99% by a wholly-owned subsidiary of the Group, as to 19.53% by Fidelidade, a subsidiary of the Group, and as to 1.58% by a subsidiary (the Group held 61.88% equity interest in such subsidiary). Therefore, the Group held 86.57% effective equity interest in Club Med.
- 7. The Company and Fidelidade, a subsidiary of the Group held 3.996% and 7.225% equity interest in Thomas Cook, respectively. Therefore, the Group held 10.14% effective equity interest in Thomas Cook.
- 8. The Group signed an agreement in February 2018 to purchase a majority stake in Lanvin. As at the date of this announcement, the transaction remained to be

- subsidiary of the Group, and as to 4.07% by a company of Fidelidade (Fidelidade held 51% equity interest in such company). Therefore, the Group held 25.01% effective equity interest in Tom Tailor.
- 10. The Group signed an agreement in March 2018 to purchase a majority stake in Wolford and intended to launch a tender offer to acquire the whole equity interest in Wolford. The project remained to be completed as at the date of this announcement
- 11. The Group held 43,50% equity interest in Caruso. The joint venture established by the Group and Pramerica-Fosun China Opportunity Fund managed by the Group held 30.40% equity interest in Caruso (the Group held 17.00% equity interest in the joint venture). Therefore, the Group held 48.67% effective equity interest in Caruso.
- 12. The joint venture established by the Group and Pramerica-Fosun China Opportunity Fund managed by the Group held 70% equity interest in St. John (the Group held 19.70% equity interest in the joint venture). Therefore the Group held 13.79% effective equity interest in \$t. John.

- 13. Belong to Fashion sector. The Group held 10% equity interest in Folli Follie through its wholly-owned subsidiary. In addition, Pramerica-Fosun China Opportunity Fund managed by the Group held 3.89% equity interest.
- 14. During the Reporting Period, the Group and the fund managed by the Group signed agreements to purchase 17.99% equity interest in Tsingtao Brewery. This transaction was completed in March 2018. The Group held 14 29% effective equity interest in Tsington Brewery
- 15. The Group held 84,9861% equity interest in Fidelidade, 80% equity interest in Multicare and 80% equity interest in Fidelidade Assistência through its whollyowned subsidiary.
- 16. Nanjing Nangang, the company's joint venture company, held 84.50% equity interest in Koller.
- 17. The Group and Nanjing Nangang jointly purchased 100% equity interest in